Market Overview

UPDATE: Valeant Posts Upbeat Q4 Profit

Related VRX
Exclusive: SunTrust Managing Director Shares Thoughts On Drug Pricing, Impact On Biotech
The Anti-Price Gouging Lead Poisoning Treatment
Valeant Pharmaceuticals: The Sell-Off Is Way Overdone (Seeking Alpha)

Valeant Pharmaceuticals International (NYSE: VRX) posted a profit in the fourth quarter.

Valeant posted its quarterly net income of $123.8 million, or $0.36 per share, versus a year-ago loss of $89.1 million, or $0.29 per share. Excluding one-time items, it earned $2.15 per share.

Its revenue jumped to $2.06 billion. However, analysts were projecting a profit of $2.06 per share on revenue of $2.06 billion.

Valeant shares gained 1.94% to $149.14 in pre-market trading.

Posted-In: profitEarnings News


Related Articles (VRX)

View Comments and Join the Discussion!